BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38300401)

  • 21. BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma.
    Givens DJ; Buchmann LO; Agarwal AM; Grimmer JF; Hunt JP
    Laryngoscope; 2014 Sep; 124(9):E389-93. PubMed ID: 24604709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
    Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
    Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer.
    Tao Y; Wang F; Shen X; Zhu G; Liu R; Viola D; Elisei R; Puxeddu E; Fugazzola L; Colombo C; Jarzab B; Czarniecka A; Lam AK; Mian C; Vianello F; Yip L; Riesco-Eizaguirre G; Santisteban P; O'Neill CJ; Sywak MS; Clifton-Bligh R; Bendlova B; Sýkorová V; Zhao S; Wang Y; Xing M
    J Clin Endocrinol Metab; 2021 Oct; 106(11):3228-3238. PubMed ID: 34273152
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
    Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
    Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRAFV600E mutation in fine-needle aspiration aspirates: Association with poorer prognostic factors in larger papillary thyroid carcinomas.
    Lee JI; Jang HW; Kim SW; Kim JW; Oh YL; Chung JH
    Head Neck; 2013 Apr; 35(4):548-53. PubMed ID: 22488961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [
    Yang T; Chen C; Pan NF; Sun LY; Jiang XL; Li JN; Tang Y; Jiang Y
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 50(6):919-924. PubMed ID: 31880125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The BRAF(V600E) mutation influences the short- and medium-term outcomes of classic papillary thyroid cancer, but is not an independent predictor of unfavorable outcome.
    Russo M; Malandrino P; Nicolosi ML; Manusia M; Marturano I; Trovato MA; Pellegriti G; Frasca F; Vigneri R
    Thyroid; 2014 Aug; 24(8):1267-74. PubMed ID: 24787545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis.
    Liu C; Chen T; Liu Z
    World J Surg Oncol; 2016 Sep; 14(1):241. PubMed ID: 27600854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?
    Walczyk A; Kowalska A; Kowalik A; Sygut J; Wypiórkiewicz E; Chodurska R; Pięciak L; Góźdź S
    Clin Endocrinol (Oxf); 2014 Jun; 80(6):899-904. PubMed ID: 24354346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates.
    Al-Salam S; Sharma C; Afandi B; Al Dahmani K; Al-Zahrani AS; Al Shamsi A; Al Kaabi J
    PLoS One; 2020; 15(4):e0231341. PubMed ID: 32315324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relationship of the BRAF(V600E) mutation and the established prognostic factors in papillary thyroid carcinomas.
    Kurt B; Yalçın S; Alagöz E; Karslıoğlu Y; Yigit N; Günal A; Deveci MS
    Endocr Pathol; 2012 Sep; 23(3):135-40. PubMed ID: 22767446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of clinical risk scores and BRAF V600E mutation status on outcome in papillary thyroid cancer.
    Niederer-Wüst SM; Jochum W; Förbs D; Brändle M; Bilz S; Clerici T; Oettli R; Müller J; Haile SR; Ess S; Stoeckli SJ; Broglie MA
    Surgery; 2015 Jan; 157(1):119-25. PubMed ID: 25482468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer?
    Nam JK; Jung CK; Song BJ; Lim DJ; Chae BJ; Lee NS; Park WC; Kim JS; Jung SS; Bae JS
    Am J Surg; 2012 Apr; 203(4):436-41. PubMed ID: 21803329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating Tumor DNA Harboring the
    Sato A; Tanabe M; Tsuboi Y; Niwa T; Shinozaki-Ushiku A; Seto Y; Murakami Y
    Thyroid; 2021 Dec; 31(12):1822-1828. PubMed ID: 34541884
    [No Abstract]   [Full Text] [Related]  

  • 35. Predicting factors of central lymph node metastasis and BRAF
    Zhou SL; Guo YP; Zhang L; Deng T; Xu ZG; Ding C; Sun WC; Zhao YW; Kong LF
    World J Surg Oncol; 2021 Jul; 19(1):211. PubMed ID: 34256769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors.
    Choi SY; Park H; Kang MK; Lee DK; Lee KD; Lee HS; Kim SW; Lee EN; Hong JC
    World J Surg Oncol; 2013 Nov; 11():291. PubMed ID: 24228637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
    Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
    Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Associations of the BRAF V600E Mutation and PAQR3 Protein Expression with Papillary Thyroid Carcinoma Clinicopathological Features.
    Gao J; Ma XP; Deng FS; Jiang L; Jia WD; Li M
    Pathol Oncol Res; 2020 Jul; 26(3):1833-1841. PubMed ID: 31758408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis.
    Li C; Lee KC; Schneider EB; Zeiger MA
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4559-70. PubMed ID: 23055546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.
    Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O
    Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.